OpenCitations
Works that cite this article, indexed by OpenCitations.
Advances in Disease Modifying Therapies for Parkinson's Disease
Trends in CNS Drug Discovery (2025)
Kambiz Hassanzadeh; M. Maral Mouradian
NRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin
Antioxidants 10(11) (2021)
Juan A. Parga; Ana I. Rodriguez-Perez; Maria Garcia-Garrote; Jannette Rodriguez-Pallares; Jose L. Labandeira-Garcia
Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
Frontiers in Pharmacology 12 (2021)
Yumin Wang; Luyan Gao; Jichao Chen; Qiang Li; Liang Huo; Yanchao Wang; Hongquan Wang; Jichen Du
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Pharmacological Reviews 74(1) (2022)
Hilary Grosso Jasutkar; Stephanie E. Oh; M. Maral Mouradian
Disaccharide trehalose in experimental therapies for neurodegenerative disorders: Molecular targets and translational potential
Pharmacological Research 183 (2022)
Alexander B. Pupyshev; Tatyana P. Klyushnik; Anna A. Akopyan; Sandeep Kumar Singh; Maria A. Tikhonova
GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders
Pharmacological Reports 74(4) (2022)
Divya Soni; Puneet Kumar
A Pivotal Role of Nrf2 in Neurodegenerative Disorders: A New Way for Therapeutic Strategies
Pharmaceuticals 15(6) (2022)
Sibel Suzen; Paolo Tucci; Elisabetta Profumo; Brigitta Buttari; Luciano Saso
Targeting ROS-Dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson’s Disease Rat Model
ACS Chemical Neuroscience 12(4) (2021)
Hany H. Arab; Marwa M. Safar; Nancy N. Shahin
Oxidopamine and oxidative stress: Recent advances in experimental physiology and pharmacology
Chemico-Biological Interactions 336 (2021)
Igor Pantic; Jelena Cumic; Sanja Radojevic Skodric; Stefan Dugalic; Claude Brodski